Skip to main content
Equibles
PTGX logo

PTGX · Protagonist Therapeutics, Inc · Metrics

Track PTGX — free

Use PTGX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$145.68 -0.26 (-0.18%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$9.43B
Shares
64.71M

PTGX metrics

72 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$145.94
Market cap
$9.43B

Price action

20 metrics
Price change (1W)
+1.0%
Price change (30D)
-2.9%
Price change (3M)
+49.6%
Price change (6M)
+58.2%
Price change (YTD)
+66.8%
Price change (1Y)
+144.5%
Trailing year
Price change (5Y)
+198.1%
52-week high
$158.62
52-week low
$56.19
Change from 52-week high
-8.1%
Change from 52-week low
+159.3%
Annualized volatility
51.2%
Annualized volatility (3M)
44.4%
Beta
0.2
RSI (14D)
49.4
Price vs SMA 50
+3.4%
Price vs SMA 200
+37.4%
Avg volume (3M)
672,298
Relative volume
0.8
Average dollar volume
$88.51M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
64.71M

Valuation

12 metrics
P / E (TTM)
141.5
Trailing earnings · reciprocal yield 0.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
33.4×
reciprocal yield 3.0%
P / book
11.2
reciprocal yield 8.9%
FCF yield
1.4%
TTM · current market cap
Buyback yield
—
P / FCF
72.2
reciprocal yield 1.4%
P / operating cash flow
71.9
reciprocal yield 1.4%
Earnings yield
0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
78.6×
reciprocal yield 1.3%
P / E historical average (5Y)
78.6×
reciprocal yield 1.3%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
20.7%
Trailing 12 months
Net margin
29.4%
Gross profit (TTM)
—
Operating profit (TTM)
$58.34M
Net income (TTM)
$82.91M
Trailing 12 months
Diluted EPS (TTM)
$1.03
FCF margin
46.3%
Effective tax rate
1.7%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-100.58

Growth

11 metrics
Revenue growth YoY
+3,749.2%
Year over year
Net income growth YoY
-147.3%
Revenue (TTM)
$281.99M
Trailing 12 months
EPS growth YoY
-148.5%
Shares change YoY
+11.8%
Year over year · more shares
Revenue CAGR (3Y)
+20.1%
Revenue CAGR (5Y)
+10.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
9.9%
Return on assets
9.4%
Debt / equity
—
Current ratio
21.7
EBITDA (TTM)
$59.88M
Free cash flow (TTM)
$130.58M
Quick ratio
21.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$420.08M
Total assets
$885.54M
Total debt
$9.83M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$131.20M
Capital expenditures (TTM)
$615,000
R&D (TTM)
$175.16M
SG&A (TTM)
—
Stock compensation (TTM)
$49.82M
R&D / revenue
62.1%
Stock compensation / revenue
17.7%

Ownership (13F)

3 metrics
13F filers
347
13F filer change QoQ
+22
Institutional ownership
118.1%

Short interest

3 metrics
Short interest
12.0%
Latest settlement · 16.4 days to cover
Days to cover
16.4d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$15.95M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1377121 CUSIP 74366E102 13F (30d) 216 filings 215 filers Visit website Investor relations